Osiris Therapeutics (OSIR) Misses Q2 EPS by 3c

Osiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of $0.03, $0.03 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $23.7 million versus the consensus estimate of $23.6 million.

“We remain laser focused on growing revenue and investing in our leading brands,” said Lode Debrabandere, Ph.D., President and Chief Executive Officer. “Despite the expiration of pass-through status for Grafix in early January, the wound care business continues to grow revenue by double-digits. The team has made tremendous progress in opening more accounts and increasing the number of patients treated with Grafix.”

For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat